Work

Effect of Beta‐Cell Function on Glucose Variability When Switching From Insulin Degludec Plus a Dipeptidyl Peptidase‐4 Inhibitor to Insulin Degludec/Liraglutide: Preliminary Results From a Pilot Study

Year: 2025

Type: article

Abstract: For patients with diabetes, achieving stable glucose control with minimal variability is highly significant. Incretin drugs have been shown to improve glycemic variability (GV), and we recently showed that a switch from a combination of a dipeptidyl peptidase (DPP)‐4 inhibitor plus basal insulin to insulin degludec/liraglutide (IDegLira) improves GV, including the mean amplitude of glycemic excursions (MAGE), using continuous glucose monitoring in hospitalized patients with Type 2 diabetes. Here, we performed a secondary analysis to identify the factors related to an improvement in MAGE when switching to IDegLira. In patients with high MAGE, the change in C‐peptide immunoreactivity during a glucagon test (ΔCPR) showed the highest correlation with the change in MAGE among the baseline patients’ characteristics ( ρ = −0.70; p < 0.05). Regression analysis confirmed a significant association between preserved CPR and amelioration of MAGE ( R 2 = 0.45; p < 0.05). Thus, this preliminary result implies that a treatment strategy that includes a glucagon‐like peptide‐1 receptor agonist might be beneficial for patients being treated with a DPP‐4 inhibitor plus basal insulin who show high GV but have preserved beta‐cell function. Trial Registration University Hospital Medical Information Network (UMIN) Center Clinical Trials Registry: UMIN 000039460

Source: International Journal of Endocrinology

DOI: 10.1155/ije/3911323